The authors identified a novel long non-coding RNA (lncRNA), DLGAP1-AS1, that exhibits oncogenic. properties in non-small-cell lung cancer (NSCLC). DLGAP1-AS1 was highly expressed in NSCLC. tissues and cells. Inhibition of lncRNA DLGAP1-AS1 suppressed NSCLC progression both in vitro and. in vivo via the miR-193a-5p/denticleless protein homolog (DTL) axis. This novel regulatory network. provides a potential therapeutic strategy for NSCLC.

Ubiquitin-specific protease 3 (USP3), a cysteine protease, is deubiquitinating enzyme. USP3 is aberrantly expressed in several types of tumors. The authors show that USP3 is an important positive regulator in gallbladder cancer progression, and that pyruvate kinase L/R plays a key role in the progression of GBC.

The authors present a workflow that allows the simultaneous measurement of the whole exome and the transcriptome by next-generation sequencing from formalin-fixed paraffin-embedded tissue sections that were analyzed by matrix-assisted laser desorption ionization mass spectrometry imaging. The data and analyses demonstrate the feasibility and reproducibility of this approach, which expands the possibilities of multi-omics integration in cancer research.

For precancerous/endometrial cancer patients with fertility maintain desire, progestin resistance is the main obstacle of conservative therapy. The authors found that brusatol, as a natural compound, suppresses progestin metabolism through regulating the NRF2-TET1-AKR1C1 pathway to sensitize precancerous/endometrial cancers to progestin and relieve progestin resistance. This study indicates that progestin combined with brusatol may enhance the treatment effects and that AKR1C1 expression patterns may serve as an important biomarker of progestin resistance in endometrial cancer.